Company
Acrivon Therapeutics
Acrivon is developing targeted therapies to improve the lives of patients.
Also known as Acrivon, Acrivon Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Acrivon Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We are a clinical stage oncology company leveraging our unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of our drug pipeline. AP3 is used to generate proprietary OncoSignature companion diagnostics to identify the patients who will benefit from our medicines.
Funding snapshot
- Total raised
- $115MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $100M2021-11-09
Funding rounds
- Round, 2021
- $100M2021-11-09, SEC form D sold, 13 investors
- Round, 2021
- $15.5M2021-01-28, SEC form D sold, 2 investors
Loading relationship preview